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Highly Active Antiretroviral Therapy (HAART) is a standard of HIV management to suppress
viral load and delay progression to AIDS. However, questions have been raised about the
use of antiretroviral therapy and how it affects quality of life (QoL) of people living with HIV/
AIDS (PLWHA). The study hence aimed to assess the QoL of PLWHA who were taking
HAART at Mizan–Tepi University Teaching Hospital (MTUTH) and identify factors associ-
ated with QoL.
Methods
A cross sectional study was conducted among PLWHA receiving HAART at MTUTH from
March 04-April 1, 2018. Patients were recruited consecutively and interviewed with struc-
tured questionnaire. A data abstraction tool was used to extract data from patient medical
records. Quality of life was assessed using the World Health Organization Quality of Life
HIV- BREF (WHOQOL-HIV-BREF) standard tool. Data was entered to Epi-Info version
3.5.3 and analyzed using SPSS version 22 for windows. A multivariable logistic regression
analysis was fitted to identify factors associated with QoL. A statistical significance was
established at a p value <0.05.
Results
A total of 240 participants with the mean age of 35.11 (SD = 9.08) years were included in the
study. This study found that 57.1% of the patients had high global score of QoL. Patients
with normal current health (AOR = 3.38, 95% CI = 1.56–7.31)) and having family support
(AOR = 3.12, 95% CI = 1.51–6.46) were positively associated with high global score of QoL,
while patients with low HAART adherence (AOR = 0.40, 95%, CI = 0.19–0.86) were nega-
tively associated with high global score of QoL.
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Conclusion
The study revealed that more than half of the participants had high global score of QoL. Nor-
mal current health and family support were associated with better global score of QoL, while
low HAART adherence was found to be associated with the lower global score of QoL.
Introduction
Human Immunodeficiency Virus (HIV) primary affects the immune system that predisposes
the victim to multiple opportunistic diseases leading to Acquired Immuno-deficiency Syn-
drome (AIDS) [1]. According to UNAIDS, there were approximately 36.7 million people
worldwide living with HIV/AIDS at the end of 2016 [2]. Most HIV infected people, approxi-
mately 95% of the total, live in developing countries. Sub-Saharan Africa has been hit especially
hard, with almost 70% of all HIV-infected patients living there [3]. Adult HIV prevalence in
Ethiopia was estimated to be 1.1% in 2016 [4].
Introduction of Highly Active Anti-Retroviral Therapy (HAART) was a major turning
point in HIV care. It uses a combination of antiretroviral medication recommended to aggres-
sively suppress viral replication and halt progress of HIV to AIDS, hence a subsequent
improvement in survival and quality of life (QoL) [5–8]. Significant efforts have been exerted
to scale-up HAART uptake in developing countries; particularly in sub–Saharan Africa, where
the epidemic has had its most devastating impact. However, there are concerns about impact
of HAART on the QoL of people living with HIV/AIDS (PLWHA), where it is influenced by
multiple factors [9–11]. According to the World Health Organization (WHO), QoL is defined
as individuals’ perceptions of their position in life in the context of the culture and value sys-
tems in which they live and in relation to their goals, standards, expectations and concerns
they have [12]. This definition implies that QoL is largely dependent on cultural, social and
environmental contexts as well as individual perception [12, 13]. QoL has been used as a crite-
rion in assessing HIV/AIDS prevention programs, clinical treatment, and harm reduction
strategies [14]. Multilevel interventions and long-term care, rehabilitation, behavioral therapy
and social supports for patients receiving treatments, and application of e-health approaches
can improve QoL of HIV patients [15].
Although HAART is usually considered as a standard of care and savior for PLWHA [8,
16], QoL of people taking Anti-retroviral Therapy (ART) remains a concern. Healthcare is
dynamic; in continuous change, aimed to increase the length and quality of survival. Conse-
quently, to increase the length and quality of survival of PLWHA who are on ART, it is essen-
tial that an evaluation of their QoL becomes more important than quantity of life. ART may
indeed prolong life but may only do so at considerable cost to the QoL of PLWHA [17]. There
is a geographical discrepancy in HIV/AIDS economic evaluation research [18]. The high cost
of ART might reduce the adherence to treatment and worsen QoL [19]. An improved QoL
and resultant ability of the patient to resume normal life, including supporting the families and
working productively will encourage long-term maintenance of treatment. However, if QOL is
poor, it impacts negatively on lifelong adherence to medication [20].
Through reflection on the sense of well-being and satisfaction experienced by people under
their current life circumstances, the assessment of QoL aims to provide a comprehensive eval-
uation of the individual’s well-being, which includes an assessment of their role functioning,
community integration and personal adjustment [21]. Previously, studies were conducted in
different parts of Ethiopia [9, 22–26], but data are scanty on QoL of PLWHA in the current
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setting. Since QoL is affected by many factors that varies from setting to setting, it is important
to evaluate the QoL at this area. Thus, the study aimed to assess the QoL and its determinants
among PLWHA who were receiving HAART at Mizan–Tepi University teaching hospital
(MTUTH).
Methods
Study setting and design
A facility based cross-sectional study was conducted at the ART clinic of MTUTH, located in
Mizan-Aman town, Southwest of Ethiopia. It provides services to the residents of Benchi Maji
zone and Gambella Regional state. At the time of data collection, 1639 patients were actively
receiving HAART at the hospital. Data was conducted from March 04-April 1, 2018.
Sampling procedure
The sample size was calculated using the single population proportion formula. Considering a
z value of 1.96 for 95% confidence interval, 50% prevalence of poor QoL and 5% of margin of
error, gives initial sample size of 384. The initial sample was adjusted using a correction for-
mula for the study population (population<10,000) giving the final sample size of 311.
The study included PLWHA aged� 18 years old who were on HAART for at least 6
months. Patients with incomplete medical records (lack of CD4 count or absence of WHO
clinical stage), and those not willing to participate were excluded from study.
All patients who visited the ART Pharmacy during data collection period, and who fulfilled
inclusion criteria were recruited for the study. Due to low patient flow, unwillingness of partic-
ipants, and incomplete medical records, only 240 patients were included in the final analysis.
Data collection instrument and process
The WHOQOL-HIV BREF was used to assess the QoL of PLWHA receiving ART. Briefly, the
tool consisted of 31 items/facets. Of 31 items, 29 items were used to measure individual QoL
across six domains while two items were used to measure patients’ perception of their general
QoL and health status. The six domains are physical, psychological, level of independence,
social relationships, environmental, and spirituality, religion, personal beliefs (SRPB). Each
item is rated in a five-point Likert scale where 1 indicates low, negative perception and 5 indi-
cate high, positive perception. However, the score for pain and discomfort, dependence of
medication, death and dying, and negative feelings and other negatively phrased items were
reversed using the formula 6-X (where X was the facet score) [12, 27, 28].
The facet score was calculated by dividing a sum of all items of the facet by four. The facet
scores within each domain were used to calculate the domain score. Hence, the domain scores
were computed by multiplying the mean of all items within the domain by four. A global score
of QoL was similarly calculated using the mean scores of all the six domains. All domain scores
ranged from 4 to 20 [12]. Higher scores in each domain indicated higher QoL for that domain
[28]. Patients’ QoL was categorized as poor if their score is below the sample mean, and good
when they scored equal or greater than the mean. The overall QoL of each patient was classi-
fied as high or low taking the sample mean global score as a reference. The tool was translated
into the local language (Amharic) and was previously validated and widely used in other set-
tings in Ethiopia [22, 24–26, 29].
Adherence to HAART was assessed by a standard Morisky Medication Adherence Predic-
tor Scale (MMAPS-8) designed for adherence measurement in chronic diseases [30, 31]. The
tool was widely used to assess medication adherence in PLWHA in Ethiopia [32, 33]. The scale
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has eight items which are used to assess patient’s HAART adherence over the past two weeks.
Each question has a response of Yes (1) or No (0) with score for item number 5 being reversed.
Accordingly, patients with a score of 0, 1–2 and�3 to the MMAPS-8 are categorized to have
high, moderate, and low levels of HAART adherence, respectively. A data abstraction format
was also used to collect patients’ clinical information from their medical records.
Data was collected by trained pharmacists. Patients were approached at the end of medica-
tion fill at the ART pharmacy. An interviewer administered questionnaire was used instead of
self-administered due to inclusion of illiterate participants in the study. First the interview was
carried out for each participants and clinical information was extracted from their respective
medical records.
The questionnaire and data abstraction format were checked thoroughly for comprehen-
siveness before commencement of the actual data collection through pre-test. The data collec-
tor made frequent checks on the data collection process to ensure data quality. The collected
data was checked for its completeness, accuracy, clarity, and consistency after conducting data
collection. Pre-test was done on 10 patients.
Data entry and analysis
The collected data was entered to Epi Info version 3.5.3 and analyzed using Statistical Package
for Social Sciences (SPSS) version 22.0 for Windows. Descriptive statistics (frequency, mean,
SD) were used for frequency distributions of responses.
A binary logistic regression analysis was undertaken to identify factors associated with high
global score of QoL. Accordingly, crude odd ratio (COR) and adjusted odd ratio (AOR) were
used to measure level of association during the bivariate and multivariable analysis, respec-
tively. A p value < 0.05 was used to declare a statistically significant association at 95% of con-
fidence interval (CI).
Ethical consideration
The study was approved by institutional review board of College of Health Sciences, Mizan-
Tepi University. A formal letter of cooperation was submitted to ART clinic of the hospital
and permission was secured before data collection. All patients were informed about the pur-
pose of the study, the importance of their participation and verbal consent was taken, and
interview were proceeded after the consent. The consent was recorded in each questionnaire.
Participation in the study was fully voluntarily and informed about their right to leave the
study at any time. No personal identifiers were included in the data and confidentiality of the
collected data was always maintained.
Results
Sociodemographic characteristics of patients
We have approached 311 patients, but data of 240 was included in the analysis giving a
response rate of 77.2% (excluded due to unwillingness to participate, incomplete medical rec-
ords, and lost medical records). A total of 240 patients with mean age of 35.11 ±9.08 years; ran-
ged from 18 to 62 years were included in the final analysis. Females comprised 63.8% of
participants. Majority of the patients (132, 55%) completed primary education and 130(54.2%)
patients were married (Table 1).
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Self-perceived health status and other health related information
Patients were asked to rate their current health status; accordingly, 26.3%, 20% and 2.1% rated
their current health as very good, neither good nor bad, and very poor, respectively. Approxi-
mately two-third of (64.6%) could not ascertain the source of HIV infection, while 71 (29.6%)
patients admitted to a sexual relationship as the source of infection. Most patients (86.25%)
had disclosed their HIV status to their relatives. Regarding support, more than half (63.33%)
of the participants reported that they had family support (Table 2).
Seventeen patients were found to be the current substance users, including Khat and alco-
hol. Adherence to HAART was assessed using MMAPS-8. Accordingly, out of 240 patients,
187 (77.90%), 20 (8.30%) and 33 (13.80%) patients had high, medium, and low HAART adher-
ence, respectively (Table 3).
Clinical information
At baseline, the mean body weight of participants was 51.83 ± 9.55 Kg, while at the time of
data collection, 55.59±10.00 Kg. Most of the participants (57.81%) had a normal BMI, with
mean of 20.48±3.58 Kg/m2. Only 33.47% of patients had baseline CD4 count�350 cells/mm3
(mean: 333.54±294.77), and 97.87% of them had the most recent CD4 count�100 cells/
mm3(mean: 594.63±347.28)). More than half of the patients were in advanced stages of HIV
(stage III and IV) during enrollment to ART care, while most of them (87.08%) had a current
Table 1. Socio-demographic characteristics of PLWHA on HAART at MTUTH, March 2018.
Variable Category Freq. Percentage
Sex Male 87 36.25
Female 153 63.75
Age (Years) � 30 87 36.25
31–40 99 41.25
>40 54 22.50
Education Cannot Read and Write 39 16.25
Primary (1–8 Grade) 132 55.00
Secondary (9–12 Grade) 50 20.83
Higher Education 19 7.90




Occupation Farmer 15 6.25
Gov’t Employee 42 17.50
Trade/Private 56 23.33
Daily Labourer 38 15.83
House Wife 50 20.83
Unemployed 23 9.58
Other� 16 6.68
Residency Rural 34 14.17
Urban 206 85.83
Having Children No 49 20.42
Yes 191 79.58
�Carpenter (2), Driver (4), Mechanic (1), Student (6), Maid (1), Retired (2)
https://doi.org/10.1371/journal.pone.0237013.t001
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WHO clinical stage I disease. Among 175 patients for whom the most recent viral load was
recorded, 88.57% had a viral load measurement of�1000 copies/ml (mean: 426.86±1334.52).
More than half (144, 60%) of the patients-initiated ART with the first line regimen (TDF+3TC
+EFV), with 184 (76.67%) remained on the same ART regimen during their treatment.
Among those patients who made a regimen change (N = 56), development of toxicity (48.21%)
was accounted as a major reason (Table 4).
HRQOL: Mean scores, level of mean scores and global sores of QoL
domains
The HRQOL was assessed using WHOQOL-HIV BREF. The internal consistency of the tool
was assessed using Cronbach’s alpha coefficient. The analysis showed that alpha value of 0.897,
Table 2. Self-perceived health status and other health related information of PLWHA on HAART at MTUTH, March 2018.
Variable Category Frequency Percentage
Perceived current health status Very poor 5 2.08
Poor 14 5.83
Neither Poor nor Good 48 20.00
Good 110 45.83
Very Good 63 26.25
Current ill Health No 171 71.25
Yes 69 28.75
Believe you were infected with HIV Unprotected Intercourse 71 29.58
Blood products 14 5.83
Unknown 155 64.58
Duration since tested +Ve for HIV (Years) � 2 150 62.50
>2 90 37.50
Disclosure HIV status to relatives No 33 13.75
Yes 207 86.25
Family members with HIV No 130 54.17
Yes 110 45.83
Number of family members affected with HIV (n = 110) 1 89 80.91
2 15 13.64
�3 6 5.45
Living environment Very bad 7 2.92
Bad 18 7.50
Neither bad nor Good 64 26.67
Good 124 51.67
Very Good 27 11.25
Family support No 88 36.67
Yes 152 63.33
Social relationship Very bad 1 0.42
Bad 8 3.33
Neither bad nor Good 9 3.75
Good 107 44.58
Very Good 115 47.92
Recent experience with HIV stigma and discrimination No 222 92.50
Yes 18 7.50
HIV: Human Immunodeficiency Virus Duration since tested positive for HIV (Months): Mean (SD) = 79.55 (44.55) Range (Min-Max) = 198(6–204)
https://doi.org/10.1371/journal.pone.0237013.t002
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which revealed the internal reliability of the questionnaire, as it is higher than the recom-
mended cut-off point (alpha> 0.7) [34].
The mean scores of each facet of QoL domains and the two general facets were determined.
The higher the score of the facets, the better global score of QoL. The scores for seven facets
were reversed so that the lower the score indicates the higher global score of QoL. The mean
scores of QoL were high in the SRPB (17.13), physical (16.34) and level of independence
(16.21) domains, while it was medium in the remaining domains (Table 5).
The mean scores of QoL were categorized into low and high scores for each domain.
Among the six domains, the largest proportions of participants scored a high QoL in SRPB
domain (64.6%) followed by psychological domain (62.5%). In contrary, a higher percentage
of participants (57.5%) scored low QoL in social relationship domain (Fig 1).
About 57.1% of the participants had a high global score of QoL, while the remain 42.9%
had low global score of QoL.
Factors associated with poor quality of life
A bivariate binary logistic regression analysis was run to identify any association between dif-
ferent sociodemographic and clinical variables with global score of QoL of the participants.
Among sociodemographic variables, educational status, occupation, marital status, and family
support were associated with high global score of QoL. In addition, HAART adherence, cur-
rent ill health, and BMI were clinical variables associated with global score of QoL.
Table 3. Health related information and drug taking behaviour of PLWHA on HAART MTUTH, March 2018.
Variable Category Frequency %
Perceived baseline quality of life Very Bad 34 14.17
Bad 46 19.17
Neither Bad nor Good 31 12.92
Good 96 40.00
Very Good 33 13.75
Ever used any substance No 166 69.17
Yes 74 30.83
Currently using any substance (n = 74) No 57 77.02
Yes 17 22.97
Type of current substance use (n = 17) Alcohol 6 35.29
Khat 11 64.71
Frequency of ART Administration per day Once 172 71.67
Twice 68 28.33
Regular follow up for HIV No 1 0.42
Yes 239 99.58
Relation with health care provider Very Bad 1 0.42
Bad 1 0.42
Neither Bad nor Good 3 1.25
Good 60 25.00
Very Good 175 72.90
Level of HAART Adherence High 187 77.90
Medium 20 8.30
Low 33 13.80
ART: Antiretroviral Therapy; HAART: Highly Active Antiretroviral Therapy; HIV: Human Immunodeficiency Virus
https://doi.org/10.1371/journal.pone.0237013.t003
PLOS ONE HQOL PLWHA receiving HAART
PLOS ONE | https://doi.org/10.1371/journal.pone.0237013 August 20, 2020 7 / 14
Table 4. Clinical information of PLWHA on HAART at MTUTH, March 2018.
Variable Category Frequency Percent
Recent BMI (n = 237) Under weight (BMI<18.5) 74 31.22
Normal BMI (18.5–24.99) 137 57.81
Overweight (25–24.99) 26 10.97
Baseline CD4 Count (n = 239) <350 159 66.53
�350 80 33.47
Recent CD4 Count (n = 235) <100 5 2.13
� 100 230 97.87
Baseline VL (n = 20) � 1000 11 55.00
> 1000 9 45.00
Recent VL (n = 175) � 1000 155 88.57
> 1000 20 11.43
Baseline WHO Clinical Stage Stage I 66 27.50
Stage II 48 20.00
Stage III 114 47.50
Stage IV 12 5.00
Recent WHO Clinical Stage Stage I 209 87.08
Stage II 24 10.00
Stage III 7 2.92
Comorbidity (at least one) No 229 95.42
Yes 11 4.58
Type of comorbidity (Total comorbidity = 12) Asthma 4 33.33
Chronic Kidney Disease 3 25.00
Hypertension 2 16.67
Heart Failure 2 16.67
Major Depressive Disorder 1 8.33
OIs (at least one) No 172 71.67
Yes 68 28.33
Type of OIs (Total OIs = 68) Tuberculosis 67 98.53
Toxoplasmosis 1 1.47
Cotrimoxazole preventive therapy No 42 17.50
Yes 198 82.50
Isoniazid preventive therapy No 50 20.83
Yes 190 79.17











Initial Regimen change No 184 76.67
Yes 56 23.33
Reasons for regimen change (n = 56) Toxicity 27 48.21
Treatment failure 13 23.21
Not documented 12 21.43
New Tuberculosis 3 5.36
Drug non-availability 1 1.79
(Continued)
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Table 4. (Continued)
Variable Category Frequency Percent
ADRs No 181 75.42
Yes 59 24.58
ADRs: Adverse Drug Reactions; BMI: Body Mass Index (Kg/m2); OIs: Opportunistic Infections; VL: Viral Load (Copies/ml).
� 2F (AZT-3TC-ATV/r), 4d (AZT-3TC-EFV for child), 4a (d4t-3TC-NVP for child), 4C (AZT-3TC-NVP for child)
�� Total duration on HAART (Years): Mean (SD) = 5.55(3.59)
https://doi.org/10.1371/journal.pone.0237013.t004
Table 5. Mean scores for each of the six QoL domain facets for PLWHA on HAART at MTUTH, March 2018.
Domains Facets Mean (SD) Domain mean score (out of
20)
General Rating Quality of Life 3.84(0.88)
Satisfaction with health 3.75(0.95)
Physical Extent to which a patient feels that physical pain prevents from doing what is needed to be done?
(REVERSED)
4.23(1.25) 16.34(3.36)
Extent a patient is bothered by any physical problems related to HIV infection (REVERSED) 4.29(1.22)
Having enough energy for everyday life 3.74(1.31)
Satisfaction with sleep 4.08(1.01)
Psychological Extent a patient enjoys life 3.76(1.02) 14.30(2.21)
Extent a patient feels his/her life to be meaningful 4.26(0.92)
Ability to concentrate 3.89(1.03)
Ability to accept bodily appearance 4.04(1.19)





Extent a patient needs any medical treatment to function in daily life (REVERSED) 4.55(0.93) 16.21(2.50)
Ability to get around 4.06(0.71)
Satisfaction with the ability to perform daily living activities 3.81(0.93)
Satisfaction with capacity for work 3.79(1.01)
Social Relationships Extent a patient feels accepted by the people he/she knows 3.80(1.16) 13.82(3.15)
Satisfaction with personal relationships 4.18(1.04)
Satisfaction with sex life 1.96(1.26)
Satisfaction with the support a patient gets from friends 3.88(1.22)
Environmental Extent a patient feels safe in daily life 3.78(1.03) 13.58(2.27)
Extent a patient’s physical environment is healthy 3.69(1.02)
Having enough money to meet a patient day 2.4(1.46)
Availability of information a patient needs in day-to-day life 2.59(1.50)
Extent a patient has the opportunity for leisure activities 3.36(1.03)
Satisfaction with the conditions of living place 3.91(1.00)
Satisfaction with access to health services 4.46(0.79)
Satisfaction with transport 2.97(1.12)
SRPB Extent a patient is bothered by people blaming for his/her HIV status (REVERSED) 4.38(1.18) 17.13(3.57)
Extent a patient fears the future (REVERSED) 4.33(1.33)
Extent a patient worries about death (REVERSED) 4.48(1.22)
Satisfaction with oneself 3.96(0.98)
Overall HRQOL 3.81(0.53) 15.23(2.12)
SRPB: Spirituality, Religion, Personal Beliefs
https://doi.org/10.1371/journal.pone.0237013.t005
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A multivariable logistic analysis was also fitted to determine predictors of QoL. Accord-
ingly, patients with normal current health (AOR = 3.38, 95% CI = 1.56–7.31) and having fam-
ily support (AOR = 3.12, 95% CI = 1.51–6.46) were found to have positive association with
global score of QoL, while patients who having low HAART adherence (AOR = 0.40, 95%,
CI = 0.19–0.86) had negative association with global score of QoL (Table 6).
Discussion
The term QoL has been used to describe the overall sense of wellbeing with respect to happi-
ness and general level of satisfaction with life. Given the longevity of life achievable with the
current therapeutic strategies for PLWHA, QoL has emerged as a significant measure of health
outcome, and quality of life enhancement as an important goal. The identification of factors
that determine QoL is important to better tailor health and social care services, and thereby
improve the functioning and wellbeing of people living with HIV.
Besides, determining the extent of QoL, this study found that factors like current health
condition, family support and HAART adherence have been found to be strongly associated
with the QoL of PLWHA. According to our study, more than half (57.1%%) of patients have a
high global QoL. In contrary, studies from Bangladesh [35] reported global QoL score of low.
The study revealed that HAART adherence and QoL has a strong association. Patients who
had a low/medium HAART adherence were 60% less likely to have a high global score of QoL
compared with patients with high HAART adherence. A study done in South Africa [36] and
Ethiopia [23] also reported the same findings that adherence is known to contribute to the
QoL of PLWHA, as persons with greater ability to adhere to their ART regimens have better
QoL. Adherence is found to improve clinical conditions of patients and suppress viral load
[37–39] which in turn influence QoL.
According to the present study, current normal health had a positive association with the
QoL. Hence, patients who reported normal current health were 3.38 times more likely to have
Fig 1. Level of mean scores of QoL domains for PLWHA on HAART at MTUTH, March 2018.
https://doi.org/10.1371/journal.pone.0237013.g001
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high global score of QoL as compared to patients who were currently ill. In line with this find-
ing, the study conducted in Nigeria [40] revealed that participants who reported being
Table 6. Multivariable logistic regression analysis of factors associated with QoL of PLWHA on HAART at MTUTH, March 2018.
Variables Global Score of QoL Bivariate analysis Multivariable analysis
High (%) Low (%) P-value COR (955 CI) P-value AOR (955 CI)
Sex
Male 48 39 - 1.00
Female 89 64 0.65 0.88(0.52–1.50)
Age
�30 58 30 0.12 1.72(0.86–3.46) 0.146 2.03(0.78–5.29)
31–40 51 48 0.88 0.95(0.49–1.85) 0.396 1.47(0.60–3.60)
>40 28 25 - 1.00 1.00
Education
Illiterate 19 20 0.058 0.32(0.10–1.04) 0.499 1.94(0.29–13.15)
Primary 66 65 0.047 0.34(0.12–0.98) 0.838 1.19(0.22–6.35)
Secondary 37 13 0.931 0.95(0.29–3.13) 0.344 2.16(0.44–10.69)
College 15 5 1.00 1.00
Occupation
Farmer� 24 29 1.00 1.00
Gov’t employee 31 11 0.006 3.40(1.42–8.17) 0.979 0.98(0.23–4.12)
Private Business 31 25 0.294 1.50(0.70–3.19) 0.322 0.61(0.23–1.63)
Unemployed 41 31 0.229 1.55(0.76–3.15) 0.544 0.75(0.29–1.93)
Other 10 6 0.232 2.01(0.64–6.34) 0.949 0.95(0.20–4.43)
Marital status
Single 12 6 0.100 2.77(0.82–9.31) 0.299 2.44(0.45–13.10)
Married 81 48 0.037 2.34(1.05–5.19) 0.333 1.70(0.58–4.98)
Divorced 31 31 0.463 1.38(0.58–3.30) 0.960 0.97(0.31–3.04)
Widowed 13 18 1.00 1.00
Current ill health
Yes 22 47 1.00 1.00
No 115 56 0.000 4.39(2.41–7.98) 0.002 3.38(1.56–7.31)
Family support
Yes 105 47 0.000 3.91(2.25–6.80) 0.002 3.12(1.51–6.46)
No 32 56 1.00 1.00
Substance use (ever)
Yes 38 36 0.23 0.71(0.41–1.24) 0.53 0.78(0.36–1.70)
No 99 67 1.00 1.00
HAART adherence
High 116 71 1.00 1.00
Medium/low 21 32 0.004 0.40(0.22–0.75) 0.018 0.40(0.19–0.86)
OIs
Yes 31 37 0.025 0.52(0.30–0.92) 0.20 1.60(0.78–3.32)
No 106 66 1.00 1.00
Current BMI (Kg/m2)
Under/Overweight 48 52 0.013 0.51(0.30–0.87) 0.15 0.61(0.32–1.19)
Normal BMI 88 49 1.00 1.00
�Farmer and daily laborer
https://doi.org/10.1371/journal.pone.0237013.t006
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currently ill had poorer QoL in all the domains. The preoccupation of patients with diseases
and the physical symptoms they experienced can impact negatively on QoL. In the absence of
current illness, PLWHA can feel independent, self-reliance and physical and psychologically
fit to execute their daily activities which helps them to feel positive about themselves.
From this finding, patients who get a continuous support from their family were 3.12 times
more likely to have high global score of QoL. The positive impact of family support on patients
QoL is also cited in previous studies [9, 41–43]. Family support is important for patients to feel
secure, enhance self-confidence, minimize stress, and discrimination. The support from family
largely depends on disclosure of sero-status, which is high in our study (86.25%). Disclosure is
found to associated with QoL [44]. Family support can also help to improve adherence to
HAART which in turn suppress viral load and improve clinical condition of patients, ulti-
mately contribute for improved QoL.
The findings of study should be interpreted with consideration of the following limitations.
The study is a single facility, cross-sectional design, hence extrapolation to other areas should
be with precaution. The study may be underpowered to detect difference among groups espe-
cially variables with multiple categories. In addition, the study included a point in time data
without follow-up. The other limitation is a measurement of adherence using MMAPS, which
is subjective by its nature and has a chance of recall bias as participants were expected to
remember two weeks lag time. In addition, since an interviewer administered questionnaire
was used, there may be social desirability bias in sensitive information such as sex life, sub-
stance use, discrimination, and social relationships.
Conclusions
Majority of the participants (57.1%) had a high global score of QoL. Normal current health
and family support were associated with better global score of QoL, while low adherence was
negatively associated with global score of QoL. Efforts should be strength to further improve
quality of life PLWHA and further research should be done with longitudinal and qualitative
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